Dianthus Therapeutics (NASDAQ:DNTH) Director Simon Read Sells 2,778 Shares

Dianthus Therapeutics, Inc. (NASDAQ:DNTH) Director Simon Read sold 2,778 shares of the company’s stock in a transaction on Wednesday, August 19th. The shares were sold at an average price of $117.55, for a total transaction of $326,553.90. Following the transaction, the director owned 2,778 shares of the company’s stock, valued at approximately $326,553.90. The trade was a 50.00% decrease in their ownership of the stock. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which is accessible through this link.

Simon Read also recently made the following trade(s):

• On Monday, August 10th, Simon Read sold 2,777 shares of Dianthus Therapeutics stock. The stock was sold at an average price of $109.55, for a total transaction of $304,220.35.

Dianthus Therapeutics Stock Performance

NASDAQ DNTH opened at $113.70 on Thursday. The firm has a 50-day simple moving average of $99.51 and a 200 day simple moving average of $84.41. Dianthus Therapeutics, Inc. has a twelve month low of $22.06 and a twelve month high of $117.88. The stock has a market cap of $6.22 billion, a PE ratio of -27.40 and a beta of 1.22.

Dianthus Therapeutics (NASDAQ:DNTH) last issued its quarterly earnings results on Tuesday, August 4th. The company reported ($0.90) earnings per share (EPS) for the quarter, missing the consensus estimate of ($0.85) by ($0.05). Dianthus Therapeutics had a negative net margin of 10,096.95% and a negative return on equity of 22.53%. The firm had revenue of $0.76 million for the quarter, compared to the consensus estimate of $0.30 million. Research analysts forecast that Dianthus Therapeutics, Inc. will post -3.83 earnings per share for the current fiscal year.

Analyst Ratings Changes

A number of equities analysts have recently issued reports on the stock. Truist Financial increased their price objective on shares of Dianthus Therapeutics from $110.00 to $128.00 and gave the company a “buy” rating in a research note on Thursday, August 6th. Wedbush lifted their target price on shares of Dianthus Therapeutics from $105.00 to $122.00 and gave the company an “outperform” rating in a research report on Wednesday, August 5th. Raymond James Financial reiterated a “strong-buy” rating and issued a $131.00 price objective on shares of Dianthus Therapeutics in a research note on Wednesday, August 5th. Guggenheim reaffirmed a “buy” rating on shares of Dianthus Therapeutics in a report on Wednesday, June 10th. Finally, HC Wainwright raised their price target on Dianthus Therapeutics from $130.00 to $158.00 and gave the company a “buy” rating in a report on Thursday, August 6th. One investment analyst has rated the stock with a Strong Buy rating, twelve have issued a Buy rating and one has issued a Sell rating to the company’s stock. According to MarketBeat, Dianthus Therapeutics currently has a consensus rating of “Moderate Buy” and a consensus target price of $124.27.

Institutional Inflows and Outflows

A number of large investors have recently made changes to their positions in DNTH. Alyeska Investment Group L.P. boosted its position in shares of Dianthus Therapeutics by 188.2% in the 2nd quarter. Alyeska Investment Group L.P. now owns 150,592 shares of the company’s stock worth $14,680,000 after purchasing an additional 98,345 shares during the last quarter. UBS AM a distinct business unit of UBS ASSET MANAGEMENT AMERICAS LLC lifted its stake in Dianthus Therapeutics by 24.8% in the second quarter. UBS AM a distinct business unit of UBS ASSET MANAGEMENT AMERICAS LLC now owns 75,396 shares of the company’s stock valued at $7,350,000 after buying an additional 14,961 shares during the period. Wellington Management Group LLP lifted its stake in Dianthus Therapeutics by 24.4% in the second quarter. Wellington Management Group LLP now owns 3,229,882 shares of the company’s stock valued at $314,849,000 after buying an additional 634,099 shares during the period. Jefferies Financial Group Inc. bought a new position in Dianthus Therapeutics during the second quarter worth about $574,000. Finally, Capstone Investment Advisors LLC acquired a new position in shares of Dianthus Therapeutics during the 2nd quarter worth about $207,000. Institutional investors and hedge funds own 47.53% of the company’s stock.

Dianthus Therapeutics Company Profile

Dianthus Therapeutics, Inc, a clinical-stage biotechnology company, develops complement therapeutics for patients with severe autoimmune and inflammatory diseases. It is developing DNTH103, a monoclonal antibody, which is in Phase 2 clinical trial, for the treatment of generalized myasthenia gravis, multifocal motor neuropathy, and chronic inflammatory demyelinating polyneuropathy. Dianthus Therapeutics, Inc was founded in 2019 and is headquartered in New York, New York.